Centrosome abnormalities in ovarian cancer

International Journal of Cancer

Volumn 113, Issue 5, 2005, Pages 746-751

  Hsu, Lih Ching ^a,b   Kapali, Malathy ^c   DeLoia, Julie A ^a,b   Gallion, Holly H ^a,b  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^c UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Centrosome abnormalities; Histologic subtype; Ovarian cancer; Prognosis; Tumor grade

Indexed keywords

GAMMA TUBULIN; PARAFFIN;

ARTICLE; CANCER GRADING; CANCER STAGING; CARCINOGENESIS; CENTROSOME; CONTROLLED STUDY; EPITHELIUM; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; OVARY; OVARY CANCER; OVARY TUMOR; PRIORITY JOURNAL; TUMOR CELL CULTURE; TUMOR GROWTH;

ADENOCARCINOMA; BLOTTING, WESTERN; CARCINOMA, ENDOMETRIOID; CENTROSOME; CHROMOSOME ABERRATIONS; CYSTADENOCARCINOMA, SEROUS; EPITHELIAL CELLS; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; HUMANS; NEOPLASM STAGING; OVARIAN NEOPLASMS; OVARY; PLOIDIES; TUMOR CELLS, CULTURED;

EID: 11944267438     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.20633     Document Type: Article

References (24)

1. Greenlee RT, Hill-Harmon MB, Murray T, Thun M. Cancer statistics, 2001. CA Cancer J Clin 2001;51:15-36.
2. Friedlander ML. Prognostic factors in ovarian cancer. Semin Oncol 1998;25:305-14.
3. Kramer A. Ho AD. Centrosome aberrations and cancer. Onkologie 2001;24:538-44.
4. Nigg EA. Centrosome aberrations: cause or consequence of cancer progression? Nat Rev Cancer 2002;2:815-25.
5. D'Assoro AB, Lingle WL, Salisbury JL. Centrosome amplification and the development of cancer. Oncogene 2002;21:6146-53.
6. Fukasawa K, Choi T, Kuriyama R, Rulong S, van de Woude GF. Abnormal centrosome amplification in the absence of p53. Science 1996;271:1744-7.
7. Xu X, Weaver Z, Linke SP, Li C, Gotay J, Wang X-W, Harris CC, Ried T, Deng C-X. Centrosome amplification and a defective G2-M cell cycle checkpoint induce genetic instability in BRCA1 exon 11 isoform-deficient cells. Mol Cell 1999;3:389-95.
8. Tutt A, Gabriel A, Bertwistle D, Connor F, Paterson H, Peacock J, Ross G, Ashworth A. Absence of Brca2 causes genome instability by chromosome breakage and loss associated with centrosome amplification. Curr Biol 1999;9:1107-10.
9. Zhou H, Kuang J, Zhong L, Kuo, WL, Gray, JW, Sahin A, Brinkley BR, Sen S. Tumor amplified kinase STK15/BTAK induces centrosome amplification, aneuploidy and transformation. Nat Genet 1998; 20:189-93.
10. Linge WL, Barrett SL, Negron VC, D'Assoro AB, Boeneman K, Liu W, Whitehead CM, Reynolds C, Salisbury JL. Centrosome amplification drives chromosomal instability in breast tumor development. Proc Natl Acad Sci USA 2002;99:1978-83.
11. Pihan GA, Purohit A, Wallace J, Malhotra R, Liotta L, Doxsey SJ. Centrosome defects can account for cellular and genetic changes that characterize prostate cancer progression. Cancer Res 2001;61:2212-9.
12. Sato N, Mizumoto K, Nakamura M, Nakamura K, Kusumoto M, Niiyama H, Ogawa T, Tanaka M. Centrosome abnormalities in pancreatic ductal carcinoma. Clin Cancer Res 1999;5:963-70.
13. Pihan GA, Wallace J, Zhou Y, Doxsey SJ. Centrosome abnormalities and chromosome instability occur together in pre-invasive carcinomas. Cancer Res 2003;63:1398-404.
14. Duensing S, Lee LY, Duensing A, Basile J, Piboonniyom S, Gonzalez S, Crum CP, Munger K. The human papilloma virus type 16 E6 and E7 oncoproteins cooperate to induce mitotic defects and genomic instability by uncoupling centrosome duplication from cell division cycle. Proc Natl Acad Sci 2000;97:10002-7.
15. Duensing S, Duensing A, Crum CP, Munger K. Human papillomavirus type 16 E7 oncoprotein induced abnormal centrosome synthesis is an early event in the evolving malignant phenotype. Cancer Res 2001;61:2356-60.
16. Hsu L-C, White RL. BRCA1 is associated with the centrosome during mitosis. Proc Natl Acad Sci 1998;95:12983-8.
17. Hsu L-C, Doan TP, White RL. Identification of a γ-tubulin-binding domain in BRCA1. Cancer Res 2001;61:7713-8.
18. Auersperg N, Wong AS, Choi KC, Kang SK, Leung PC. Ovarian surface epithelium: biology, endocrinology, and pathology. Endocr Rev 2001;22:255-88.
19. Goodman MT, Correa CN, Tung, K-H, Roffers SD, Wu XC, Young JL, Wilkens LR, Carney ME, Howe HL. Stage at diagnosis of ovarian cancer in the United States, 1992-1997. Cancer 2003;97:2648-59.
20. Feeley KM, Wells M. Precursor lesions of ovarian epithelial malignancy. Histopathology 2001;38:87-95.
21. Vergote I, De Brabanter J, Fyles A, Bertelsen, K, Einhorn N, Sevelda P, Gore ME, Karn J, Verrelst H, Sjovall K, Timmerman D, Vandewalle J, et al. Prognostic importance of degree of differentiation and cyst rupture in stage I invasive epithelial ovarian carcinoma. Lancet 2001;357:176-82.
22. Jazaeri AA, Lu K, Schmandt R, Harris CP, Rao PH, Sotiriou C, Chandramouli GVR, Gershenson DM, Liu ET. Molecular determinants of tumor differentiation in papillary serous ovarian carcinoma. Mol Carcinog 2003;36:53-9.
23. Tirkkonen M, Johannsson O, Agnarsson BA, Olsson H, Ingvarsson S, Karhu R, Tanner M, Isola J, Barkardottir RB, Borg A, Kallioniemi O-P. Distinct somatic genetic changes associated with tumor progression in carriers of BRCA1 and BRCA2 germ-line mutations. Cancer Res 1997;57:1222-7.
24. Hashiguchi Y, Tsuda H, Yamamoto K, Inoue O, Ogita S. Combined analysis of p53 and RB pathways in epithelial ovarian cancer. Hum Pathol 2001;32:988-96.